ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC : Episode 8
Opinion
Video
Emerging Therapies in RCC: Shaping Future Treatment Sequences
Author(s):
Experts discuss the role of belzutifan and tivozanib in the treatment paradigm for advanced renal cell carcinoma (RCC), including key findings from the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.
Video content above is prompted by the following:
- With belzutifan and tivozanib gaining traction in advanced RCC, how do you see these agents fitting into the treatment paradigm?
- Please briefly highlight the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.
Latest CME
View All
Video
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Apr 8th 2025 - May 14th 2025
online-activity
Video
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Apr 7th 2025 - Apr 8th 2026
online-activity
Video
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas
Apr 3rd 2025 - May 9th 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
